Oragenics Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics

Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company advancing brain-targeted therapies through proprietary intranasal delivery technology, has announced a strategic collaboration with Receptor.AI to accelerate the development of new drug candidates for neurological conditions. The partnership will apply AI-based receptor modeling to optimize binding profiles for compounds acquired in 2023, supporting Oragenics' expansion beyond its lead candidate, ONP-002, in concussion.

CEO Janet Huffman stated that the collaboration underscores the company's evolution into a diversified neurological therapeutics developer, combining artificial intelligence and precision delivery to streamline preclinical discovery and enhance capital efficiency. This strategic move represents a significant step in Oragenics' transformation from a single-product focused company to a broader neurological therapeutics platform.

The collaboration with Receptor.AI brings sophisticated computational approaches to Oragenics' drug discovery pipeline. AI-based receptor modeling represents a cutting-edge approach in pharmaceutical development, potentially reducing the time and resources required to identify promising therapeutic candidates. This methodology could significantly accelerate the identification of compounds with optimal binding characteristics for neurological targets.

Oragenics is striving to revolutionize neurological care through proprietary intranasal delivery technology that has the potential to enable targeted, non-invasive therapeutics for brain-related conditions. The company's lead candidate, ONP-002, is advancing with the goal of becoming the first FDA-approved treatment for concussion, while the platform technology has the potential to open pathways to address neurodegenerative diseases, CNS disorders, and other neurological conditions.

The partnership announcement follows Oragenics' acquisition of compounds in 2023, which now become the focus of the AI-driven optimization efforts. This strategic alignment of recent acquisitions with advanced computational methods demonstrates the company's systematic approach to building a diversified neurological therapeutics portfolio. The collaboration represents a convergence of two innovative technologies: Oragenics' specialized delivery platform and Receptor.AI's artificial intelligence capabilities.

For the biotechnology industry, this partnership exemplifies the growing trend of combining traditional pharmaceutical development with advanced computational approaches. The integration of AI in drug discovery processes has the potential to transform how neurological conditions are treated, potentially leading to more effective therapies with reduced development timelines. This approach could set new standards for efficiency in neurological drug development.

The latest news and updates relating to OGEN are available in the company's newsroom at https://ibn.fm/OGEN. The full press release detailing this strategic collaboration can be viewed at https://ibn.fm/Wo8YZ. This partnership represents a significant milestone in Oragenics' corporate development strategy and reflects the increasing importance of computational methods in modern pharmaceutical research and development.